Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE): $0.63

0.02 (+3.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYNE Stock Price Chart Interactive Chart >

Price chart for ZYNE

ZYNE Price/Volume Stats

Current price $0.63 52-week high $2.94
Prev. close $0.61 52-week low $0.49
Day low $0.60 Volume 375,346
Day high $0.64 Avg. volume 331,026
50-day MA $0.58 Dividend yield N/A
200-day MA $0.92 Market Cap 28.83M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavioral symptoms, in patients with ≥90% methylation of the FMR1 gene, compared to those treated with pl

Yahoo | January 11, 2023

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | January 8, 2023

UPDATE 2-Zynerba delays genetic disorder drug data on enrollment challenge

Zynerba Pharmaceuticals Inc on Wednesday delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing difficulties in enrolling patients amid a rise in respiratory illnesses. The company's experimental drug is currently undergoing a late-stage study in patients between 3 and 17 years of age suffering from Fragile X syndrome, which is one of the most common causes of inherited intellectual disability that impact about 1 in 7,000 males and 1 in 11,000 females, according to the U.S. Centers for Disease Control and Prevention (CDC). In October, U.S. doctors had warned that a surge in cases of respiratory syncytial virus (RSV) is coinciding with an increase in COVID transmission and an earlier-than-normal flu season, raising t...

Yahoo | December 21, 2022

Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of the RECONNECT trial DEVON, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies

Yahoo | December 21, 2022

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology

Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented positive long-term 38-week data from the Phase 2 INSPIRE trial with Zygel in childr

Yahoo | December 5, 2022

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo 12.86%
3-mo -10.65%
6-mo -48.36%
1-year -75.77%
3-year -87.62%
5-year -94.23%
YTD 18.87%
2022 -81.60%
2021 -12.73%
2020 -45.36%
2019 103.37%
2018 -76.28%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6685 seconds.